journal article·2020-01-01Open access

Lactoferrin-tethered betulinic acid nanoparticles promote rapid delivery and cell death in triple negative breast and laryngeal cancer cells

Asim Halder, Megha Jethwa, Pritha Mukherjee, Subarna Ghosh, Suvadra Das, A. B. M. Helal Uddin, Arup Mukherjee, Urmi Chatterji, Partha Roy

Abstract

Cancer management presents multifarious problems. Triple negative breast cancer (TNBC) is associated with inaccurate prognosis and limited chemotherapeutic options. Betulinic acid (BA) prevents angiogenesis and causes apoptosis of TNBC cells. NIH recommends BA for rapid access in cancer chemotherapy because of its cell-specific toxicity. BA however faces major challenges in therapeutic practices due to its limited solubility and cellular entree. We report lactoferrin (Lf) attached BA nanoparticles (Lf-BAnp) for rapid delivery in triple negative breast (MDA-MB-231) and laryngeal (HEp-2) cancer cell types. Lf association was confirmed by SDS-PAGE and FT-IR analysis. Average hydrodynamic size of Lf-BAnp was 147.7 ± 6.20 nm with ζ potential of -28.51 ± 3.52 mV. BA entrapment efficiency was 75.38 ± 2.70% and the release mechanism followed non-fickian pattern. Impact of Lf-BAnp on cell cycle and cytotoxicity of triple negative breast cancer and its metastatic site laryngeal cancer cell lines were analyzed. Lf-BAnp demonstrated strong anti-proliferative and cytotoxic effects, along with increased sub-G1 population and reduced number of cells in G1 and G2/M phases of the cell cycle, confirming reduced cell proliferation and significant cell death. Speedy intracellular entry of Lf-BAnp occurred within 30 min. Lf-BAnp design was explored for the first time as safer chemotherapeutic arsenals against complex TNBC conditions.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Infant Nutrition and Health · Pediatric Hepatobiliary Diseases and Treatments · ATP Synthase and ATPases Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Technology, University of Calcutta

Department of Pharmaceutical Technology, JIS University

Cancer Research Laboratory, Department of Zoology, University of Calcutta

Basic Science and Humanities Department, University of Engineering and Management, University Area

Kulliyyah Of Pharmacy, International Islamic University Malaysia, Kuantan Campus

Department of Biotechnology, Malulana Abul Kalam Azad University of Technology (formerly WBUT)

Department of Pharmaceutical Technology, Adamas University

Funding

UGC · DBT · CSIR · Research Management Centre IIUM

References (44)

Show source-provided references
1. 10.1016/S0169-409X(02)00044-310.1016/S0169-409X(02)00044-3 ↗
2. 10.1016/j.drudis.2010.08.00610.1016/j.drudis.2010.08.006 ↗
3. 10.1016/S0168-3659(99)00248-510.1016/S0168-3659(99)00248-5 ↗
4. 10.1016/j.addr.2010.10.00810.1016/j.addr.2010.10.008 ↗
5. 10.1039/c2cs15344k10.1039/c2cs15344k ↗
6. 10.1021/bm500300910.1021/bm5003009 ↗
7. Eiznhamer DA, Xu ZQ. Betulinic acid: a promising anticancer candidate. IDrugs. 2004;7(4):359–373.
8. Clarkson BD, Burchenal JH. Preliminary screening of antineoplasic drugs. Prog Clin Cancer. 1965;1:625–629.
9. Fulda S, Friesen C, Los M, et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 1997;57(21):4956–4964.
10. 10.1038/nm1095-104610.1038/nm1095-1046 ↗
11. 10.1002/mc.2044710.1002/mc.20447 ↗
12. 10.1186/s13046-016-0457-110.1186/s13046-016-0457-1 ↗
13. 10.1021/je200531k10.1021/je200531k ↗
14. 10.1016/S0304-3835(01)00718-210.1016/S0304-3835(01)00718-2 ↗
15. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106–116.
16. 10.1016/j.breast.2010.03.02610.1016/j.breast.2010.03.026 ↗
17. 10.1177/205031211455197410.1177/2050312114551974 ↗
18. 10.1111/j.1699-0463.1999.tb01499.x10.1111/j.1699-0463.1999.tb01499.x ↗
19. 10.1016/S1476-5586(03)80034-910.1016/S1476-5586(03)80034-9 ↗
20. 10.2967/jnumed.117.19228610.2967/jnumed.117.192286 ↗
21. 10.1016/j.canlet.2004.03.02910.1016/j.canlet.2004.03.029 ↗
22. 10.3168/jds.2009-292610.3168/jds.2009-2926 ↗
23. 10.1016/j.currproblcancer.2018.07.01010.1016/j.currproblcancer.2018.07.010 ↗
24. 10.1371/journal.pone.010181810.1371/journal.pone.0101818 ↗
25. 10.2174/13892011280472485510.2174/138920112804724855 ↗
26. 10.1016/j.jpba.2006.09.02610.1016/j.jpba.2006.09.026 ↗
27. 10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
28. 10.1016/j.biomaterials.2013.11.05610.1016/j.biomaterials.2013.11.056 ↗
29. 10.1016/S0006-2952(02)01296-010.1016/S0006-2952(02)01296-0 ↗
30. 10.1016/j.biomaterials.2015.01.01410.1016/j.biomaterials.2015.01.014 ↗
31. 10.1073/pnas.132235611110.1073/pnas.1322356111 ↗
32. 10.1016/B978-0-12-802215-3.00006-910.1016/B978-0-12-802215-3.00006-9 ↗
33. 10.1016/S0022-3565(24)38274-610.1016/S0022-3565(24)38274-6 ↗
34. 10.1016/0003-2697(86)90176-410.1016/0003-2697(86)90176-4 ↗
35. 10.1016/S0039-9140(02)00102-910.1016/S0039-9140(02)00102-9 ↗
36. 10.1016/0378-5173(83)90064-910.1016/0378-5173(83)90064-9 ↗
37. 10.4155/tde.13.610.4155/tde.13.6 ↗
38. 10.1080/10837450.2018.142543310.1080/10837450.2018.1425433 ↗
39. 10.4155/tde.13.2110.4155/tde.13.21 ↗
40. 10.1023/B:BIOM.0000027693.60932.2610.1023/B:BIOM.0000027693.60932.26 ↗
41. 10.1038/srep3206210.1038/srep32062 ↗
42. 10.1016/j.ijpharm.2014.12.07010.1016/j.ijpharm.2014.12.070 ↗
43. 10.1038/sj.onc.120802110.1038/sj.onc.1208021 ↗
44. 10.2217/nnm.15.19910.2217/nnm.15.199 ↗